{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:30:42Z","timestamp":1793327442259,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000380","name":"Guy's & Saint Thomas' Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000380","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.canlet.2026.218894","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:25:27Z","timestamp":1792020327000},"page":"218894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Repurposing antimalarial drug atovaquone in combination with radiation and PD-L1 checkpoint blockade to enhance antitumour response in head and neck squamous cell carcinoma (HNSCC)"],"prefix":"10.1016","volume":"662","author":[{"given":"Abul","family":"Azad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Yu-ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-7422","authenticated-orcid":false,"given":"Selvam","family":"Thavaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-4527","authenticated-orcid":false,"given":"Ifigenia","family":"Vasiliadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-5619","authenticated-orcid":false,"given":"Tony","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3378-3748","authenticated-orcid":false,"given":"Tammy","family":"Kalber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-3948","authenticated-orcid":false,"given":"Anthony","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2020","key":"10.1016\/j.canlet.2026.218894_bib1","first-page":"7","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218894_bib2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13014-015-0377-9","article-title":"Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials","volume":"10","author":"Du","year":"2015","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0202-2","article-title":"Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer","volume":"51","author":"Byeon","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218894_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194694","article-title":"The therapeutic potential of imidazole or quinone-based compounds as radiosensitisers in combination with radiotherapy for the treatment of head and neck squamous cell carcinoma","volume":"14","author":"Azad","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218894_bib6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218894_bib7","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218894_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib10","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","article-title":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85","volume":"46","author":"Overgaard","year":"1998","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ijrobp.2023.11.055","article-title":"Randomized phase 3 trial of the hypoxia modifier nimorazole added to radiation therapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD)","volume":"119","author":"Thomson","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2026.218894_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12308","article-title":"The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia","volume":"7","author":"Ashton","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218894_bib14","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2015-07-660506","article-title":"Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent","volume":"128","author":"Xiang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218894_bib15","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1158\/1078-0432.CCR-20-4128","article-title":"Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non-small cell lung cancer","volume":"27","author":"Skwarski","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218894_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ctrv.2013.10.002","article-title":"Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)","volume":"40","author":"Cohen","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218894_bib17","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-18-1286","article-title":"Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2\/\u03b2-Catenin signaling","volume":"18","author":"Gupta","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218894_bib18","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1186\/s12885-023-11585-9","article-title":"Atovaquone inhibits colorectal cancer metastasis by regulating PDGFR\u03b2\/NF-\u03baB signaling pathway","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218894_bib19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.bbrc.2018.06.049","article-title":"The anti-malarial atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt\/AMPK\/mTOR inhibition","volume":"504","author":"Ke","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2026.218894_bib20","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41586-025-08994-0","article-title":"Radiation-induced amphiregulin drives tumour metastasis","volume":"643","author":"Piffk\u00f3","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218894_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41420-021-00675-x","article-title":"Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management","volume":"7","author":"Yang","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.canlet.2026.218894_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218894_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2026.218894_bib24","article-title":"Metformin induces apoptosis and inhibits migration by activating the AMPK\/p53 axis and suppressing PI3K\/AKT signaling in human cervical cancer cells","volume":"23","author":"Chen","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2026.218894_bib25","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","article-title":"eIF2\u03b1 phosphorylation is pathognomonic for immunogenic cell death","volume":"25","author":"Bezu","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2026.218894_bib26","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/bloodadvances.2019000499","article-title":"Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation","volume":"3","author":"Stevens","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.canlet.2026.218894_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1431089","article-title":"eIF2\u03b1 phosphorylation: a hallmark of immunogenic cell death","volume":"7","author":"Bezu","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218894_bib28","first-page":"1697","article-title":"Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma","volume":"8","author":"Gao","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218894_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-084176","article-title":"Correlation of the treatment sensitivity of patient-derived organoids with treatment outcomes in patients with head and neck cancer (SOTO): protocol for a prospective observational study","volume":"14","author":"Vasiliadou","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.canlet.2026.218894_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218894_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218894_bib33","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1038\/s41467-021-22619-w","article-title":"Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218894_bib34","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-17-0235","article-title":"Cisplatin alters antitumor immunity and synergizes with PD-1\/PD-L1 inhibition in head and neck squamous cell carcinoma","volume":"5","author":"Tran","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218894_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.591139","article-title":"Tumor-specific antibody, cetuximab, enhances the in situ vaccine effect of radiation in immunologically cold head and neck squamous cell carcinoma","volume":"11","author":"Jin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218894_bib36","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.bbrc.2018.04.042","article-title":"Targeting mitochondrial respiration as a therapeutic strategy for cervical cancer","volume":"499","author":"Tian","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2026.218894_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153529","article-title":"Atovaquone at clinically relevant concentration overcomes chemoresistance in ovarian cancer via inhibiting mitochondrial respiration","volume":"224","author":"Guo","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.canlet.2026.218894_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12935-022-02550-w","article-title":"KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma","volume":"22","author":"Gao","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2026.218894_bib39","article-title":"Therapeutic efficacy of external beam radiotherapy combined with anti-PD-L1 inhibition in a preclinical syngeneic head and neck cancer model","volume":"56","author":"Banu","year":"2026","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.oraloncology.2019.06.026","article-title":"Establishment of syngeneic murine model for oral cancer therapy","volume":"95","author":"Chen","year":"2019","journal-title":"Oral Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0194599812442037","article-title":"Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer","volume":"147","author":"Judd","year":"2012","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.canlet.2026.218894_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/0008-5472.CAN-11-1831","article-title":"ERK1\/2 regulation of CD44 modulates oral cancer aggressiveness","volume":"72","author":"Judd","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218894_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106012","article-title":"The mouse oral carcinoma (MOC) model: a 10-year retrospective on model development and head and neck cancer investigations","volume":"132","author":"Kono","year":"2022","journal-title":"Oral Oncol."},{"key":"10.1016\/j.canlet.2026.218894_bib44","doi-asserted-by":"crossref","first-page":"55804","DOI":"10.18632\/oncotarget.18437","article-title":"Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells","volume":"8","author":"Clavijo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218894_bib45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12964-025-02160-9","article-title":"Atovaquone-induced activation of the PERK\/eIF2\u03b1 signaling axis mitigates metabolic radiosensitisation","volume":"23","author":"Feng","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2026.218894_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218894_bib47","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-18-1522","article-title":"Oral mucosal organoids as a potential platform for personalized cancer therapy","volume":"9","author":"Driehuis","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218894_bib48","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by Co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218894_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","article-title":"Tumor organoid-T-cell coculture systems","volume":"15","author":"Cattaneo","year":"2020","journal-title":"Nat. Protoc."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:35:28Z","timestamp":1793324128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":49,"alternative-id":["S0304383526006580"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218894","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing antimalarial drug atovaquone in combination with radiation and PD-L1 checkpoint blockade to enhance antitumour response in head and neck squamous cell carcinoma (HNSCC)","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218894"}}